DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma (ex-Nova Decision) | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* GTP TECHNOLOGY *


 

2000 - Midi-Pyrénées
Labège
(near Toulouse)
www.gtptech.com

 

Contract, Manufacturing
(also, Design, Drugs)
Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers
Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production
Clients: Pharma industry, Biotechs, Research labs
contact@gtptech.com

Age: 11 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Pease (Christopher) [M.Sc., ex-Millipore], also Managing dir. Darlington Life Science
Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology]
Oper.Dir.-COO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology], also chairman
Tech.Dir.-CTO: Mozo (Julien) [Ph.D.]
Fin.Dir.-CFO:
BusDev: Hountondji (Séverine) [M.Sc. Insa]
Financers (Hist.): privately owned, undisclosed

Turnover (M€) : 1.32 (2009), 1.34 (2008), 1.1 (2007)
Total funding (M€) : n.a.
Last funding (M€) : 0.45
Focus : Multiple
Position : Subcontractor
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2011 .00 Nomination : Christopher Pease 'also Managing dir. Darlington Life Science) as CEO, replacing Éric Devic, founder, new COO, also chairman ORGN [10 years]
2010 .11 Partnering research agreement with Indicia to combine competencies for Ab-Ag R&D [10 years]
2010 .04 Launch of catalogue of recombinant proteins for research, ready-to-use proteins and on demand proteins MKTG [9 years]
2006 .06 Certification : approval by regional Cancer-Bio-Santé cluster of L. lactis research program INFO [5 years]
2005 .04 Launch of Eiffel Biostructure platform with two partners, AliX and NMRtec, to extend services to structural analysis MKTG [4 years]
2004 .12 Seed financing : 0.45 M€, by undisclosed investors SFIN [4 years]
2003 .12 Partnering supply agreement with Pierre Fabre on recombinant protein R&D [3 years]
2003 .01 Company move from Toulouse base to Labège (near Toulouse) ORGL [2 years]
2000 .10 Company founded by Éric Devic, as a spin-off from the Protein Engineering Department of P. Sabatier University in Toulouse, France ORGF [0 year]

Actualisation / Updating: 27-Sep-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2011. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende